Latest news with #MattSchmidt
Yahoo
21 hours ago
- General
- Yahoo
'Let's go have some fun:' APS gets school year started
Aug. 20—The doors were opened wide across the Austin Public Schools District on Wednesday morning as the district opened up its 2025-26 school year. Complete with a celebratory atmosphere, students funneled through the doors of Austin High School on a day that staff sees as always being a happy one. "The building's different," said AHS Principal Matt Schmidt. "When there are no kids it's quiet. It's not as fun in the summer. We get a lot done, but it's so much better when there are teachers and kids in the building. Much different energy." Part of the reason for the energy on display for opening day is to create a welcoming atmosphere that students can get into, which of course includes a new class of incoming freshmen. "We want to make it fun and inviting," Schmidt said. "That's what we're trying to do. You've got kids at all different levels. You got kids in eighth grade going into ninth grade. It's a big building. It can be a little scary so you want to make sure they are feeling welcome. You got seniors that have been here for a few years and kind of know what's going on." "Just creating some excitement," he added. This marks a slightly earlier start from years past and that's because of a pair of things. First, it allows the district to spread more breaks out through the year, especially during long periods of time where perhaps there are no holidays to break things up. "When it comes to the spring, you have two months without a break. Those are hard," Schmidt said. "Holiday breaks are a little bit longer (between) and it helps with learning." However, it's also due to construction on Oakland Avenue West as well as work within the district. After reaching a certain dollar amount in work, districts in the State of Minnesota are allowed to request a waiver from the state to start earlier before Labor Day. To that end, the district has completed a large number of projects over the summer leading into the new school year. In Austin High School alone, Hastings Gym received new flooring, Christgau Hall was newly painted as well as the third floor and the outside of the building was power washed. Looking down the line, Schmidt said that they are eyeing a completion date for the weight room renovation toward the end of October. Funded through the Thielen Foundation, renovation will completely make-over the weight room. "We're getting wall wraps in the next couple weeks and then flooring is going in," Schmidt said. "We're ready to put that down and really, we're just waiting on equipment." All that was left Wednesday was to get the new year under way. "Let's go have some fun," Schmidt said. Solve the daily Crossword
Yahoo
21 hours ago
- General
- Yahoo
'Let's go have some fun:' APS gets school year started
Aug. 20—The doors were opened wide across the Austin Public Schools District on Wednesday morning as the district opened up its 2025-26 school year. Complete with a celebratory atmosphere, students funneled through the doors of Austin High School on a day that staff sees as always being a happy one. "The building's different," said AHS Principal Matt Schmidt. "When there are no kids it's quiet. It's not as fun in the summer. We get a lot done, but it's so much better when there are teachers and kids in the building. Much different energy." Part of the reason for the energy on display for opening day is to create a welcoming atmosphere that students can get into, which of course includes a new class of incoming freshmen. "We want to make it fun and inviting," Schmidt said. "That's what we're trying to do. You've got kids at all different levels. You got kids in eighth grade going into ninth grade. It's a big building. It can be a little scary so you want to make sure they are feeling welcome. You got seniors that have been here for a few years and kind of know what's going on." "Just creating some excitement," he added. This marks a slightly earlier start from years past and that's because of a pair of things. First, it allows the district to spread more breaks out through the year, especially during long periods of time where perhaps there are no holidays to break things up. "When it comes to the spring, you have two months without a break. Those are hard," Schmidt said. "Holiday breaks are a little bit longer (between) and it helps with learning." However, it's also due to construction on Oakland Avenue West as well as work within the district. After reaching a certain dollar amount in work, districts in the State of Minnesota are allowed to request a waiver from the state to start earlier before Labor Day. To that end, the district has completed a large number of projects over the summer leading into the new school year. In Austin High School alone, Hastings Gym received new flooring, Christgau Hall was newly painted as well as the third floor and the outside of the building was power washed. Looking down the line, Schmidt said that they are eyeing a completion date for the weight room renovation toward the end of October. Funded through the Thielen Foundation, renovation will completely make-over the weight room. "We're getting wall wraps in the next couple weeks and then flooring is going in," Schmidt said. "We're ready to put that down and really, we're just waiting on equipment." All that was left Wednesday was to get the new year under way. "Let's go have some fun," Schmidt said. Solve the daily Crossword
Korea Herald
07-07-2025
- Business
- Korea Herald
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres ® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres ® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres ® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY 90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres ® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY 90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres ® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres ® for HCC treatment." For more information and details on how to incorporate SIR-Spheres ® into your practice, please contact Sirtex at info-use@ About SIR-Spheres ® SIR-Spheres ® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres ® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit
Cision Canada
07-07-2025
- Business
- Cision Canada
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma Français
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /CNW/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres ® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres ® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres ® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY 90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres ® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY 90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres ® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres ® for HCC treatment." For more information and details on how to incorporate SIR-Spheres ® into your practice, please contact Sirtex at [email protected]. About SIR-Spheres ® SIR-Spheres ® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres ® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit APM-US-010-06-25
